Spruce Biosciences Inc (OQ:SPRB)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 2001 Junipero Serra Blvd., Suite 640
DALY CITY CA 94104-5401
Tel: N/A
Website: www.sprucebiosciences.com
IR: See website
<
Key People
Michael G. Grey
Chairman of the Board
Richard A. King
Chief Executive Officer, Director
Chris Barnes
Vice President, Biometrics
Michael Huang
Chief Medical Officer
   
Business Overview
Spruce Biosciences, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for endocrine disorders. The Company's development product candidate, tildacerfont, is a non-steroidal therapy that offers disease control for patients suffering from congenital adrenal hyperplasia (CAH). Tildacerfont is a non-steroidal, oral antagonist of the corticotropin-releasing hormone receptor 1 (CRF1) receptor, which is the receptor for corticotropin-releasing factor (CRF). By blocking the CRF1 receptor, tildacerfont enables to address the uncontrolled cortisol feedback regulatory pathway in CAH and reduce the production of adrenocorticotropic hormone (ACTH) in the pituitary, limiting the amount of androgen produced downstream from the adrenal gland. Tildacerfont also enables treating physicians to lower the supraphysiologic glucocorticoid doses given to CAH patients to near physiologic levels.
Financial Overview
For the six months ended 30 June 2020, SpruceBiosciences Inc revenues was not reported. Net lossincreased 58% to $11.6M. Higher net loss reflects Researchand development increase of 76% to $10.2M (expense),Interest Expense increase from $0K to $166K (expense),Stock-based Compensation in SGA increase of 98% to $79K(expense). Basic Earnings per Share excluding ExtraordinaryItems decreased from -$0.33 to -$0.52.
Employees: 15 as of Jun 30, 2020
Reporting Currency: U.S. Dollars
Enterprise value: $540.12M as of Jun 30, 2020
Annual revenue (TTM): $0.00M as of Jun 30, 2020
EBITDA (TTM): -$17.19M as of Jun 30, 2020
Net annual income (TTM): -$17.35M as of Jun 30, 2020
Free cash flow (TTM): -$14.85M as of Jun 30, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 23,163,593 as of Oct 14, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.